Last $4.01 USD
Change Today +0.07 / 1.78%
Volume 373.5K
NBS On Other Exchanges
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/3/14 - $8.29
52 Week Low
11/21/14 - $3.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc., a biotechnology company, develops cell based therapeutics. It is developing a Phase III targeted cancer immunotherapy product to enhance the destruction of cancer initiating cells; a Phase II ischemic repair product candidate to treat damaged heart muscle following a heart attack; a Phase II immune modulation product candidate to treat type 1 diabetes and steroid resistant asthma; and an investigational technology to repair or replace damaged or aged tissue, cells, and organs. The company, through its subsidiary, Progenitor Cell Therapy, offers contract development and manufacturing services. It also collects, processes, and stores umbilical cord blood units and adult stem cells. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

108 Employees
Last Reported Date: 03/13/14
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $945.0K
Chief Financial Officer
Total Annual Compensation: $190.6K
Chief Scientific Officer, President of Progen...
Total Annual Compensation: $494.2K
Chief Visionary Officer, Director, Chief Scie...
Total Annual Compensation: $586.5K
Chief Medical Officer
Total Annual Compensation: $331.5K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

NeoStem, Inc. Announces Initial Positive Data from Phase 2 PreSERVE AMI Clinical Trial

NeoStem, Inc. announced initial positive data from its 161 patient Phase 2 PreSERVE AMI (or acute myocardial infarction) clinical trial. These data are based on all enrolled patients being treated and having received six month follow-up for imaging and twelve month median length follow up for mortality, adverse events, serious adverse events (SAEs) and major adverse cardiac events (MACE). Highlights of the initial results include: A statistically significant mortality benefit (p<0.05) in patients treated with NBS10 (also known as AMR-001) as compared to the placebo group; there were no deaths in the treatment group. A statistically significant dose-dependent reduction in SAEs (p<0.05). Observation of a dose-dependent numerical decrease in MACE. MACE occurred in 14% of control subjects, in 17% of subjects of who received less than 14 million CD34 cells, in 10% of subjects who received greater than 14 million CD34 cells, and in 7% of subjects who received greater than 20 million CD34 cells. When correcting for the time to stent implantation in all subjects, patients treated with CD34 cells were seen to have a statistically significant dose-dependent improvement in their ejection fraction (p<0.05). Independent from time to stent implantation, a statistically significant improvement in ejection fraction (p<0.05) for patients treated with a dose of greater than 20 million CD34 cells compared to placebo was observed. No meaningful difference in perfusion, as evidenced by SPECT imaging, between the treatment and the control group from baseline to 6 months in resting total severity score (RTSS) suggesting this may not be a future suitable tool to assess NBS10, which is consistent with U.S. Food and Drug Administration (FDA) guidance that mortality and MACE are the appropriate approvable endpoints to determine efficacy of a cellular therapy for cardiac disease as opposed to imaging endpoints.

Neostem, Inc. - Special Call

To discuss on PreSERVE AMI Data

Neostem, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 05:00 PM

Neostem, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 05:00 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: Robin L. Smith, Executive Chairman and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $4.01 USD +0.07

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.44 USD +0.03
Cesca Therapeutics Inc $1.11 USD +0.02
Nuo Therapeutics Inc $0.29 USD -0.02
Pluristem Therapeutics Inc $2.61 USD +0.03
Vericel Corp $2.84 USD +0.065
View Industry Companies

Industry Analysis


Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.4x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at